Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol
Introduction Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There is limited data on the 3-month isoniazid and rifapentine (3H...
Saved in:
| Main Authors: | Turyahabwe Stavia, Barbara Castelnuovo, Christine Sekaggya-Wiltshire, Kelly E Dooley, Grace Banturaki, Irene Mbabazi, Ruth Mirembe Nabisere, Lucy Alinaitwe, Brian Otaalo, Florence Aber, Juliet Nampala, Rogers Owori, Josephine Bayigga, Jonathan Mayito, Eva Agnes Odongpiny Laker, Moorine Penninah Sekadde, Jotam Pasipanodya, Stella Zawedde‐Muyanja |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/12/e088389.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda
by: A. Musinguzi, et al.
Published: (2024-02-01) -
A mathematical model for the study of latent tuberculosis under 3HP and 1HP regimens
by: Erick M. D. Moya, et al.
Published: (2024-11-01) -
Growth of HP functions in tubes
by: Richard D. Carmichael, et al.
Published: (1981-01-01) -
3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients
by: A. Kinikar, et al.
Published: (2024-09-01) -
Hp and pH: Implications for the Eradication of Heliobacter pylori
by: Richard H Hunt
Published: (1993-01-01)